2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162111
    SARS-CoV-2-IN-73 98%
    SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker.
    SARS-CoV-2-IN-73
  • HY-162113
    Antibacterial agent 174 2896196-09-9 98%
    Antibacterial agent 174 (Compound 5g) is a antibacterial agent. Antibacterial agent 174 has potent anti-infective potential in vivo and appreciable pharmacokinetic profiles. Highly active antibacterial agent 174 has favorable biofilm removal performance, low hemolysis and acceptable mammalian cell toxicity.
    Antibacterial agent 174
  • HY-162146
    NS3-IN-1 98%
    NS3-IN-1 (compound 302) is a potent helicase (NS3) inhibitor. NS3-IN-1 shows an potent inhibitor for yellow fever helicase.
    NS3-IN-1
  • HY-16251A
    Hetacillin 3511-16-8
    Hetacillin is a beta-lactam antibiotic that is part of the aminopenicillin family.
    Hetacillin
  • HY-162550
    Jobosic acid 223611-93-6 98%
    Jobosic acid, a saturated fatty acid, is a selective SARS-CoV-2 inhibitor. Jobosic acid inhibits Mpro and spike-RBD/ACE-2 interaction with IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid shows viral entry inhibition for the omicron SARS-CoV-2 variant.
    Jobosic acid
  • HY-162559
    SDH-IN-16 98%
    SDH-IN-16 (compound 5aa) is a potent inhibitor of Succinate Dehydrogenase, with the IC50 of 1.62 μM. SDH-IN-16 displays a broad spectrum of antifungal activity against F. graminearum, B. cinerea, S. sclerotiorum, and R. solani, with the corresponding EC50 values of 0.12, 4.48, 0.33, and 0.15 μg/mL, respectively.
    SDH-IN-16
  • HY-162572
    Bitipazone 13456-08-1 98%
    Bitipazone, diacetylbis(piperidinethyl)thiourea cysteine ester (I), has potent anticoccidial activity. Bitipazone showed significant efficacy and good tolerability in rabbits and turkeys, and in chronic toxicity tests, bitipazone was tolerated in turkeys at concentrations below 90 ppm in feed. Pharmacokinetic studies show that bitipazone is eliminated slowly from the blood and organs of these animal species.
    Bitipazone
  • HY-162590
    ECIN 66160-25-6 98%
    ECIN is a copper-responsive inhibitor of wild-type UPEC strains. ECIN inhibits Uropathogenic Escherichia coli (UPEC) with an IC50 value of 336 ng/mL in the absence of copper.
    ECIN
  • HY-162598
    CET-1 98%
    CET-1 is an antiviral agent that inhibits SARS-CoV-2. CET-1 significantly prevents pseudovirus from entering ACE2h cells.
    CET-1
  • HY-162604
    SARS-CoV-2-IN-90 98%
    SARS-CoV-2-IN-90 (compound 3i) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research.
    SARS-CoV-2-IN-90
  • HY-162615
    Antibacterial agent 225 98%
    Antibacterial agent 225 (compound 12a-2) simultaneously exerts excellent bifunctional effects of fungal inhibition and immune activation.
    Antibacterial agent 225
  • HY-162624
    Quorum sensing-IN-5 98%
    Quorum sensing-IN-5 is a RpfF-targeted quorum-sensing inhibitor. Quorum sensing-IN-5 inhibits Xanthomonas oryzae pv oryzae (Xoo) and Xanthomonas axonopodis pv. citri (Xac) with EC50 values of 9.91 μg/mL and 7.04 μg/mL. Quorum sensing-IN-5 has antimicrobial activity.
    Quorum sensing-IN-5
  • HY-162656
    DHFR-IN-19 41927-06-4 98%
    DHFR-IN-19 (Compound 2g) is a selective inhibitor for TbDHFR with Ki of 9 nM. DHFR-IN-19 exhibits antiparasitic activity against Trypanosoma brucei with an EC50 of 14.5 μM.
    DHFR-IN-19
  • HY-162696
    mCMQ069 3025257-02-4 98%
    mCMQ069 is an orally active and potent antimalarial. mCMQ069 has potential for a single-dose cure and/or 28-day chemoprevention.
    mCMQ069
  • HY-162707
    RA-0002323-01 98%
    RA-0002323-01 is an antiviral agent targeting viral helicase and is an active compound from Heli-SMACC, a collection of small molecules targeting helicase.
    RA-0002323-01
  • HY-162818
    Antibacterial agent 237 98%
    Antibacterial agent 237 (compound Ru-8) is a bacteriostatic agent for Staphylococcus aureus, with MIC of 0.78-1.56 μg/mL. Antibacterial agent 237 destroys bacterial cell membranes, changes their permeability, and induces bacteria to produce Reactive Oxygen Species, leading to bacterial death without causing drug resistance. Antibacterial agent 237 has low hemolytic toxicity to rabbit red blood cells and Raw 264.7 cells, and has significant antibacterial effects against Staphylococcus aureus in mouse skin wound infection models and Bacillus major larvae infection models.
    Antibacterial agent 237
  • HY-162884
    β-Glucuronidase-IN-4 2208619-76-3 98%
    EcGUS-IN-1 (Compound E-9) is a non-competitive β-glucuronidase inhibitor, with an IC50 of 2.68 μM and a Ki value of 1.64 μM. EcGUS-IN-1 can improve gastrointestinal adverse events (GIAE) caused by Escherichia coli infection by inhibiting E. coli β-glucuronidase activity.
    β-Glucuronidase-IN-4
  • HY-162899
    DXR-IN-3 1465907-72-5 98%
    DXR-IN-3 is a DXR inhibitor that specifically targets Toxoplasma gondii. DXR-IN-3 shows in vitro activity against the TgDXR enzyme, with an IC50 value of 0.62 μM and a Ki value of 0.19 μM. DXR-IN-3 can inhibit the proliferation of Toxoplasma, with an IC50 value of 5.46 μM.
    DXR-IN-3
  • HY-162957
    LasR-IN-5 98%
    LasR-IN-5 (compound 3C) is a LasR antagonist with an IC50 of 1.37 μM, demonstrating a 77% inhibition of biofilm formation in Pseudomonas aeruginosa. LasR-IN-5 also exhibits quorum sensing (QS) inhibition activity and has potential applications in Pseudomonas aeruginosa infection research.
    LasR-IN-5
  • HY-163015
    RNA polymerase-IN-1 2447106-74-1 98%
    RNA polymerase-IN-1 (compound 4) is s DNA-dependent RNA polymerase inhibitor. RNA polymerase-IN-1 inhibits CYP isozymes.
    RNA polymerase-IN-1
Cat. No. Product Name / Synonyms Application Reactivity